Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Challenges in the transition to model-based development.

Thaddeus H Grasela1, Jill Fiedler-Kelly, Cynthia A Walawander

  • 1Cognigen Corporation. ted.grasela@cognigencorp.com

The AAPS Journal
|December 16, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing Pharmacoequity in Low- and Middle-Income Countries via Model Informed Drug Development.

Clinical and translational science·2026
Same author

Improvements in Data Quality Can Boost Efficiency and Reduce Development Costs: A Pharmacometric CRO's Perspective.

The AAPS journal·2025
Same author

Physiologically based pharmacokinetic modeling of hydroxyurea: Implications for dose adjustment in patients with renal insufficiency.

Journal of pharmaceutical sciences·2025
Same author

A Physiologically Based Pharmacokinetic Modeling Approach to Assess the Potential for Drug Interactions Between Trofinetide and CYP3A4-Metabolized Drugs.

Clinical therapeutics·2024
Same author

Expanding regulatory science: Regulatory complementarity and reliance.

Clinical and translational science·2023
Same author

Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin<sup>®</sup>) in Patients with Non-squamous Non-small Cell Lung Cancer.

European journal of drug metabolism and pharmacokinetics·2023
Same journal

Updated Recommendations for the Bioanalysis of Antibody-Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community.

The AAPS journal·2026
Same journal

In vivo Predictive Dissolution Test Using Biorelevant Bicarbonate Buffer for High-dose Free Acid Drug.

The AAPS journal·2026
Same journal

Whole-Body Pharmacokinetics of Ionizable Lipid, mRNA, and the Expressed Antibody following Intravenous Administration of mRNA-Loaded Lipid Nanoparticles.

The AAPS journal·2026
Same journal

Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation.

The AAPS journal·2026
Same journal

Guiding the Molnupiravir Tablet Formulation Using Physiologically Based Biopharmaceutics Modeling and Successfully Establishing Dissolution Safe Space.

The AAPS journal·2026
Same journal

Correction: Nanotechnology-enhanced Natural Products for Cancer Chemoprevention: Molecular Mechanisms and Clinical Translation.

The AAPS journal·2026
See all related articles

Implementing model-based drug development requires significant effort. To overcome obstacles, focus on infrastructure, process guidelines, and integrated teams for successful pharmacometric modeling and simulation.

Area of Science:

  • Pharmacometrics
  • Drug Development
  • Computational Science

Background:

  • Pharmacometric modeling and simulation are crucial but often implemented ad hoc in drug development.
  • This inefficient approach hinders the transition to model-based drug development.
  • Current challenges include data availability, high discard rates, and resistance to using modeling and simulation in decision-making.

Purpose of the Study:

  • To identify critical elements for successful implementation of model-based drug development.
  • To address the obstacles hindering the integration of modeling and simulation into drug development programs.
  • To outline a strategic approach for realizing the full value of modeling and simulation.

Main Methods:

  • The study emphasizes a strategic, process-oriented approach rather than specific technical methodologies.

Related Experiment Videos

  • It focuses on the necessary components for effective integration of modeling and simulation.
  • Key elements identified include infrastructure, process development, and organizational/cultural changes.

    • Main Results:

    • Successful model-based development hinges on three critical elements: robust infrastructure, defined processes, and integrated teams.
    • Infrastructure involves efficient data pooling across trials and programs.
    • Process development requires guidelines for application and assessment, while organizational change necessitates multidisciplinary teams trained in modeling and simulation.

    Conclusions:

    • A mature process capability for modeling and simulation is essential for effective drug development.
    • Developing integrated infrastructure, clear processes, and fostering a supportive organizational culture are critical for success.
    • These advancements will enable the full realization of the benefits of model-based drug development.